Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


AACR 2024: Study Reports Activity With Linvoseltamab in Resistant Myeloma

By: Celeste L. Dixon
Posted: Monday, April 15, 2024

Linvoseltamab induced responses in patients with relapsed or refractory multiple myeloma, according to recent pivotal results of the LINKER-MM1 clinical trial. The agent, a bispecific antibody, targets both B-cell maturation antigen and CD3-expressing T cells, noted Sundar Jagannath, MBBS, of the Icahn School of Medicine at Mount Sinai, New York, and colleagues. The team presented their work on the 117 patients in the 200-mg dosing cohorts (phases I and II) during the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT001).

For these cohorts at data cutoff, the overall response rate—the primary outcome—was 71%, which included a complete response or better rate of 46%. Among all patients with a complete response or better, 39% had achieved undetectable measurable residual disease (MRD). Significantly, frequent deep responses were observed across high-risk subgroups, including patients with stage III disease (representing 18% of the cohorts’ patients) and those with extramedullary (excluding paramedullary) plasmacytomas of 2 cm or greater (16% of the patients): overall response rate, 62% and 53%, respectively; complete response or better, 43% and 26%, respectively. Additionally, the patients’ median age was 70, 17% were Black, 39% had high-risk cytogenetics, and 82% had triple-class–refractory disease.

In terms of safety, cytokine-release syndrome occurred with generally predictable timing with use of linvoseltamab, according to the study authors. Any-grade cytokine-release sundrome occurred in nearly half of treated patients (46%). Additionally, an every-4-weeks response–adapted schedule in patients who achieved a very good partial response or better after 24 weeks of intravenous linvoseltamab (first every week, then every 2 weeks) “may provide a substantial benefit for patient convenience and is associated with a reduced infection rate,” they noted. Infections occurred in 73% of patients, with grade 3 or 4 infections reported in 34%.

The median duration of follow-up was 11.1 months. Estimated probabilities at 12 months of ongoing response, progression-free survival, and overall survival were 78%, 69%, and 75%, respectively.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.